Ssris | CARLAT PUBLISHING

CLINICAL UPDATE

Viibryd Goes Generic, But Is It Worth Prescribing?

January 1, 2023

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has no financial relationships with companies related to this material.

Goodbye Viibryd, hello vilazodone. This novel medication has missed the mark in a lot of trials, but it still has a narrow niche in the crowded field of antidepressants.

Pregnancy and PMDD at the Mood Summit

December 5, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

This podcast brings you up to date on how to manage premenstrual dysphoric disorder and safe prescribing during pregnancy.

RESEARCH UPDATE

Who Responds to SSRIs in PTSD?

October 30, 2022

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

SSRIs are often used in PTSD, but it is not clear that they work for all kinds of trauma. Trials of SSRIs are generally positive in women and people with a history of sexual trauma, while trials involving combat-related trauma tend to be negative. The current study aimed to better identify predictors of response.

RESEARCH UPDATE

SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

October 1, 2022

Joshua Feder, MD

Dr. Feder, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.

Throwback Thursday: Treating Sexual Side Effects

September 29, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Today on throwback Thursday, learn how Viagra treats depression – well, you can probably guess how, but here’s a surprise: Viagra treats sexual dysfunction in women as well as men, and it we’ll show you how in this update of our very first podcast, May 13, 2019. Oh those were simpler times.

10 Psychopharm Commandments: Med Withdrawal

September 26, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

When to stop meds quickly, and when to do it slowly, in #2 of our 10 Commandment series.

Rethinking Topiramate

August 1, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.

Management of Psychogenic Polydipsia

July 11, 2022

Victoria Hendrick, MD and Zachary Davis

Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.

Uncommon Tips: Which Is Better—Citalopram or Escitalopram?

June 1, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Citalopram and escitalopram are very similar drugs, but there are reasons to prefer one over the other.

CLINICAL UPDATE

Antidepressants: When Dosage Matters

April 5, 2022

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When it comes to antidepressants, bigger is not better. Here we review the optimal dose ranges for antidepressants, describe how higher doses can worsen symptoms, and show you how to talk to patients about the issue.